Tags

Type your tag names separated by a space and hit enter

COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
J Antimicrob Chemother. 2020 07 01; 75(7):1667-1670.JA

Abstract

A novel coronavirus disease (COVID-19), caused by infection with SARS-CoV-2, has swept across 31 provinces in China and over 40 countries worldwide. The transition from first symptoms to acute respiratory distress syndrome (ARDS) is highly likely to be due to uncontrolled cytokine release. There is an urgent need to identify safe and effective drugs for treatment. Chloroquine (CQ) exhibits a promising inhibitory effect. However, the clinical use of CQ can cause severe side effects. We propose that hydroxychloroquine (HCQ), which exhibits an antiviral effect highly similar to that of CQ, could serve as a better therapeutic approach. HCQ is likely to attenuate the severe progression of COVID-19, inhibiting the cytokine storm by suppressing T cell activation. It has a safer clinical profile and is suitable for those who are pregnant. It is cheaper and more readily available in China. We herein strongly urge that clinical trials are performed to assess the preventive effects of HCQ in both disease infection and progression.

Authors+Show Affiliations

Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, China. Center for Medical Research and Innovation, Shanghai Pudong Hospital, Fudan University, Shanghai, China.Department of Rheumatology & Immunology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.Department of Rheumatology & Immunology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32196083

Citation

Zhou, Dan, et al. "COVID-19: a Recommendation to Examine the Effect of Hydroxychloroquine in Preventing Infection and Progression." The Journal of Antimicrobial Chemotherapy, vol. 75, no. 7, 2020, pp. 1667-1670.
Zhou D, Dai SM, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother. 2020;75(7):1667-1670.
Zhou, D., Dai, S. M., & Tong, Q. (2020). COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. The Journal of Antimicrobial Chemotherapy, 75(7), 1667-1670. https://doi.org/10.1093/jac/dkaa114
Zhou D, Dai SM, Tong Q. COVID-19: a Recommendation to Examine the Effect of Hydroxychloroquine in Preventing Infection and Progression. J Antimicrob Chemother. 2020 07 1;75(7):1667-1670. PubMed PMID: 32196083.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. AU - Zhou,Dan, AU - Dai,Sheng-Ming, AU - Tong,Qiang, PY - 2020/3/21/pubmed PY - 2020/6/25/medline PY - 2020/3/21/entrez SP - 1667 EP - 1670 JF - The Journal of antimicrobial chemotherapy JO - J Antimicrob Chemother VL - 75 IS - 7 N2 - A novel coronavirus disease (COVID-19), caused by infection with SARS-CoV-2, has swept across 31 provinces in China and over 40 countries worldwide. The transition from first symptoms to acute respiratory distress syndrome (ARDS) is highly likely to be due to uncontrolled cytokine release. There is an urgent need to identify safe and effective drugs for treatment. Chloroquine (CQ) exhibits a promising inhibitory effect. However, the clinical use of CQ can cause severe side effects. We propose that hydroxychloroquine (HCQ), which exhibits an antiviral effect highly similar to that of CQ, could serve as a better therapeutic approach. HCQ is likely to attenuate the severe progression of COVID-19, inhibiting the cytokine storm by suppressing T cell activation. It has a safer clinical profile and is suitable for those who are pregnant. It is cheaper and more readily available in China. We herein strongly urge that clinical trials are performed to assess the preventive effects of HCQ in both disease infection and progression. SN - 1460-2091 UR - https://www.unboundmedicine.com/medline/citation/32196083/full_citation L2 - https://academic.oup.com/jac/article-lookup/doi/10.1093/jac/dkaa114 DB - PRIME DP - Unbound Medicine ER -